CHIMERIC THERAPEUTICS LIMITED — Board/Management Information 2021

Aug 5, 2021

ASX Announcement

==> picture [262 x 53] intentionally omitted <==

August 6, 2021

CHIMERIC APPOINTS DR YI LIN TO CELLULAR IMMUNOTHERAPY SCIENTIFIC ADVISORY BOARD

• Chimeric has initiated new Cellular Immunotherapy Scientific Advisory Board (CI-SAB) to gain expert guidance on the development of its growing pipeline

• Dr Yi Lin, Chair of the Cellular Therapeutics Group at Mayo Clinic, joins Chimeric’s new CI-SAB as its inaugural member

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce the appointment of Dr Yi Lin as the inaugural member of its newly established Cellular Immunotherapy Scientific Advisory Board (CI-SAB).

Dr Lin is an internationally recognized leader and pioneer in the development of cellular immunotherapies, having participated in many of the first in human CAR T cell therapy trials and multiple phase 2 cellular immunotherapy clinical trials.

Dr Lin is currently the Chair of the Cellular Therapeutics Cross Disciplinary Group at Mayo Clinic Cancer Center, an Associate Professor of Medicine, and a consultant in the Division of Hematology and the Division of Experimental Pathology at Mayo Clinic in Rochester, Minnesota, USA.

Chimeric Therapeutics is committed to bringing the promise of cell therapy to life for more patients with cancer. With a growing pipeline of cellular immunotherapies Chimeric has initiated a new Cellular Immunotherapy Scientific Advisory Board (CI-SAB) to ensure Chimeric’s development is informed by the latest scientific research as well as expert practical and clinical perspectives. The CI-SAB will be made up of world class experts who have been directly involved in the successful development of multiple cellular immunotherapies.

The new CI-SAB will work in parallel with the existing Glioblastoma Scientific Advisory Board (GSAB) chaired by Christine Brown.

“To deepen our commitment to conducting leading edge scientific research and developing best in class cellular immunotherapies we have initiated a Cellular Immunotherapy Scientific Advisory Board (CI-SAB). We are thrilled to have Dr Lin as the inaugural member of this board as her expertise in the development of cellular therapies will provide us with invaluable input as we advance the development of our pipeline,” said Jennifer Chow, Chief Operating Officer, Chimeric Therapeutics.

LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA

CHIMERIC THERAPEUTICS LIMITED | 1

==> picture [262 x 53] intentionally omitted <==

Dr Lin is a key committee member of SITC (Society for Immunotherapy for Cancer), the IMWG (International Working Group on Myeloma), CIBMTR (Centre for International Blood and Marrow Transplant Research) and iwCART, the International Workshop on CAR T. Dr Lin is also the author of over a hundred publications, including many pivotal cell therapy consensus statements and practice guidelines.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric Therapeutics is currently in a phase 1 clinical trial for its CHM 1101 asset (CLTX CAR T). CLTX CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM) developed by scientists at the City of Hope Medical Centre in California.

Chimeric also recently announced the expansion of their pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CAR T directed at CDH17. CHM 2101 is currently in preclinical development with a planned move to the clinic in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow Chief Operating Officer Chimeric Therapeutics P: +9087238387 W: www.chimerictherapeutics.com

Media

Matthew Wright NWR Communications P: +61 451 896 420 E: matt@nwrcommunications.com.au

LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA

CHIMERIC THERAPEUTICS LIMITED | 2